Ana María Gómez

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer

Antonio Torres, ML Maestro, Ana María Gómez et al. · British Journal of Cancer · 1996 · 69 citations · Full text

Medicine, Immunology, Pathology +8

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

David Vivas, Inmaculada Roldán, Raquel Ferrandis et al. · Revista Española de Cardiología (English Edition) · 2018 · 69 citations

Thrombosis, Venous Disease, Venous Thrombosis +13

Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancer

Marina Pollán, Gonzálo Varela, Antonio Torres et al. · International Journal of Cancer · 2003 · 54 citations · Full text

Surgical Oncology, Prognosis, Pathology +16

Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status

Tamara Fernández‐Marcelo, Ana María Gómez, Irene Pascua et al. · Journal of Experimental & Clinical Cancer Research · 2015 · 48 citations · Full text

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

Susana Hernández-Prieto, Andrea Espiau Romera, Marı́a A. Ferrer et al. · Clinical & Translational Oncology · 2014 · 44 citations · Full text

Cancer Immunosurveillance, Medicine, Novel Scoring System +10